Pharsight

Neuraceq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7907135 LIFE MOLECULAR Image display and image displaying method for gradation correction
Mar, 2029

(4 years from now)

US7807135 LIFE MOLECULAR Stilbene derivatives and their use for binding and imaging amyloid plaques
Mar, 2029

(4 years from now)

Neuraceq is owned by Life Molecular.

Neuraceq contains Florbetaben F-18.

Neuraceq has a total of 2 drug patents out of which 0 drug patents have expired.

Neuraceq was authorised for market use on 19 March, 2014.

Neuraceq is available in solution;intravenous dosage forms.

Neuraceq can be used as neuraceq is a radioactive diagnostic agent for positron emission tomography (pet) imaging of the brain to estimate p-amyloid neuritic plaque density in adult patients with cognitive impairment.

Drug patent challenges can be filed against Neuraceq from 21 March, 2018.

The generics of Neuraceq are possible to be released after 18 March, 2029.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 21, 2019

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using FLORBETABEN F-18 ingredient

NCE-1 date: 21 March, 2018

Market Authorisation Date: 19 March, 2014

Treatment: Neuraceq is a radioactive diagnostic agent for positron emission tomography (pet) imaging of the brain to estimate p-amyloid neuritic plaque density in adult patients with cognitive impairment

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

NEURACEQ family patents

Family Patents